Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 28, 2010 Luke Timmerman	Orexigen Drug Shows Potential as "Two-Fer" Against Obesity and Diabetes Orexigen's latest drug aims at treating both diabetes and obesity.
The Motley Fool June 29, 2010 Brian Orelli	Diabetes Drug Development Pops and Drops When companies present at a major meeting, there's bound to be both.
The Motley Fool February 8, 2011 Esterhuizen & Sellitti	Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch.
The Motley Fool March 17, 2005 Stephen D. Simpson	Patience Rewarded at Last Amylin's battle to get Symlin approved was long and difficult, but success will have its rewards. Should investors take a shot?
The Motley Fool July 8, 2008 Brian Lawler	Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards.
The Motley Fool November 24, 2010 Brian Orelli	Profit From the United States of Diabetes Half the country could have an early form by 2020.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool September 15, 2006 Brian Lawler	Glaxo's Burgeoning Blockbuster With a deep drug pipeline filled with potential blockbusters for nearly every major disease, and an attractive 3% dividend yield, Glaxo makes a fine investment opportunity for investors willing to brave the pharmaceutical sector.
The Motley Fool November 30, 2007 Brian Orelli	Analyzing Amylin Amylin Pharmaceuticals holds its R&D day to update investors on the marketing strategy of its two diabetes products, as well as the development of its pipeline.
BusinessWeek January 9, 2006 Arlene Weintraub	Bucking The Odds at Amylin With Ginger Graham at the helm, Amylin Pharmaceuticals has two approved diabetes drugs.
The Motley Fool September 20, 2010 Brian Orelli	Potential Blockbuster, No Me-Too About It A diabetes-fighting duo do it right this time.
The Motley Fool January 31, 2011 Brian Orelli	5 Drugmakers Headed Back to the Drawing Board Sometimes an FDA rejection is more of a to-do list.
The Motley Fool October 2, 2007 Brian Orelli	Amylin's Bittersweet FDA News Diabetes drug moves ahead, but not as much as the company wanted. If the FDA rejection was due to safety issues, that wouldn't bode well for Amylin's plans to develop the active ingredient in SYMLIN as a weight-loss drug. Investors, take note.
The Motley Fool March 14, 2008 Brian Orelli	Weighing In on Obesity Drugs Could investing in drugmakers that produce weight-loss drugs help fatten your wallet?
The Motley Fool April 5, 2005 Stephen D. Simpson	Can Obesity Fatten Your Wallet? Obesity is an increasingly serious problem, but could it also be a major opportunity for health-care companies? Investors should spend a little due diligence on the pharmaceutical side.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
Science News October 13, 2007 Janet Raloff	Food for Thought: Diminishing Obesity's Risks Mouse data suggest that, properly managed, obesity can be benign.
The Motley Fool April 15, 2011 Luke Timmerman	Amylin, Alkermes Shares Jump as EU Regulators Recommend Diabetes Drug Will this drug be approved in Europe?
The Motley Fool September 22, 2010 Brian Orelli	Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown.
BusinessWeek May 27, 2010 Michelle Cortez	Karo Bio's Prescription: Cheaper Drug Approval A Swedish company seeks a lower-cost review for its cholesterol drug.
Chemistry World November 18, 2010 Hayley Birch	'Hunger hormone' activating enzyme holds promise as obesity target Blocking a key gut enzyme involved in the hunger response can reduce weight gain in mice, say US and Taiwanese researchers. The approach could eventually lead to treatments for obesity in humans that would work by damping down hunger pangs.
The Motley Fool November 9, 2010 Brian Orelli	Arena Pharmaceuticals Scores Some Points Overall, the recent Bloom-DM study leaves Arena in a slightly better position than it was in before the data was released, but this battle to get lorcaserin approved is far from over.
BusinessWeek September 1, 2009 Catherine Arnst	Opportunities in the Obesity Epidemic Drugmakers are ratcheting up research into treatments for gout and other ills that plague the overweight.
Science News October 6, 2007 Janet Raloff	Food for Thought: Diminishing Obesity's Risks Mouse data suggest that, properly managed, obesity can be benign.
The Motley Fool November 30, 2007 Brian Orelli	Increased Potency Increases Stock Price Sirtris Pharmaceuticals publishes an article this week in Nature that characterized its discovery of drugs that are 1000 times more potent than resveratrol, the compound found in red wine that makes mice live longer and lowers blood sugar levels in obese mice.
Wired October 2006 Thomas Goetz	The Thin Pill 75 million Americans may have something called metabolic syndrome. How Big Pharma turned obesity into a disease - then invented the drugs to cure it.
The Motley Fool March 17, 2011 Brian Orelli	Taking a Bite Out of Amylin's Obesity Drug Potential Amylin Pharmaceuticals and Takeda announce they were putting a hold on the development of their obesity drug combination pramlintide/metreleptin due to safety issues.
The Motley Fool July 16, 2010 Tom Hughes	Lessons Learned About the Outlook for New Obesity Drug Approval The recent FDA advisory committee meeting on Vivus' weight loss pill proved to us, once again, how incredibly difficult it is to successfully develop and register new drugs for obesity.
The Motley Fool September 2, 2010 Luke Timmerman	Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb San Diego-based Orexigen Therapeutics has found a partner to help it compete in the growing market for drugs to combat obesity, Japan-based Takeda Pharmaceutical.
The Motley Fool September 23, 2010 Brian Orelli	Ugly Side Effects Won't Derail This Drug Side effects don't matter much when there are no other treatment options, as in Cushing's disease.
The Motley Fool June 27, 2011 Brian Orelli	Data Galore, but Where's the FDA Approval? Presentations at the American Diabetes Association won't help with approvals.
The Motley Fool July 8, 2011 Luke Timmerman	Amylin, Alkermes Once-Weekly Diabetes Drug Passes Heart Trial What does this mean for the drug companies?
The Motley Fool July 12, 2010 Ryan McBride	Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009.
Managed Care December 2003 Thomas Morrow	Can Amylin Analogue Lead To Better Diabetes Control? Maintaining tight glucose control is difficult to accomplish, but adding amylin to the mix may be the answer.
The Motley Fool July 14, 2010 Luke Timmerman	Vivus Faces Turning Point Tomorrow Thursday's the big day. All eyes will be on Vivus and the FDA's decision on their new obesity drug
The Motley Fool April 16, 2010 Brian Orelli	It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet.
Chemistry World September 24, 2010 Andrew Turley	End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use.
The Motley Fool February 20, 2009 Brian Orelli	The Skinny on Diabetes Drugs The goal of diabetes drugs is to get the patient's blood glucose levels under control, but one class of drugs, called GLP1 agonists, have a nice side effect: weight loss. Which pharma companies can benefit?
The Motley Fool June 25, 2010 Brian Orelli	Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
The Motley Fool September 30, 2011 Brian Orelli	A Drug Market That's 366 Million Strong Diabetes drugs have potential.
The Motley Fool February 12, 2010 Brian Orelli	Don't Ignore This Potential Blockbuster Five trials later, Roche's diabetes drug taspoglutide seems like a winner.
The Motley Fool July 9, 2010 Brian Orelli	2 Days, 1 Blockbuster, Fate Unknown GlaxoSmithKline heads before a marathon two-day Food and Drug Administration advisory panel review of its diabetes drug Avandia.
The Motley Fool December 31, 2009 Brian Orelli	2010 FDA Decisions to Watch It's a pivotal year for these drugmakers.
HHMI Bulletin Fall 2012 Sarah C. P. Williams	The Fat You Can't See Without the liver acting as a filter and energy producer, a person can't survive, and no artificial organ can perform all of its duties. But in one in three Americans -- and similar numbers in other developed nations -- the liver has lost its luster.
The Motley Fool March 2, 2011 Susmita Chatterjee	How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others?
Nursing Management January 2012 Lawrence et al.	Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support.
The Motley Fool February 22, 2010 Brian Orelli	Warning: Avandia Could Cause Drool Among Trial Lawyers An unintended side effect of Glaxo's Avandia might be excessive salivation among trial lawyers. A 342-page report by the Senate Finance Committee is painting the diabetes drug in a not-so-great light.
The Motley Fool August 23, 2005 Stephen D. Simpson	A Cure for Amylin's Stock? Shares moved up after promising results from a diabetes-drug test. But will the gains last?
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.